Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio
June 21, 2023 07:30 ET | Blue Water Biotech, Inc.
CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
June 14, 2023 07:30 ET | Blue Water Biotech, Inc.
CINCINNATI, Ohio, June 14, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), a biotechnology company spanning multiple sectors, today announced the signing of an Asset Purchase...
Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 12, 2023 18:32 ET | Blue Water Biotech, Inc.
CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced its financial results for...
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
May 10, 2023 12:15 ET | Blue Water Biotech, Inc.
CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global...
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
April 26, 2023 15:44 ET | Blue Water Biotech, Inc.
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay...
Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®
April 25, 2023 08:00 ET | Blue Water Biotech, Inc.
CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management...
Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company
April 24, 2023 08:00 ET | Blue Water Vaccines Inc.
CINCINNATI, April 24, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant...
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
April 20, 2023 07:30 ET | Blue Water Vaccines Inc.
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference...
Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine
April 12, 2023 08:30 ET | Blue Water Vaccines Inc.
CINCINNATI, April 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a biopharmaceutical company developing transformational vaccines to address...
Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights
March 09, 2023 08:30 ET | Blue Water Vaccines Inc.
CINCINNATI, March 09, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced its financial results for the fiscal year ended December...